LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 200

Search options

  1. Article ; Online: Autoimmune neurology-a rapidly evolving field.

    Sellner, Johann

    Wiener medizinische Wochenschrift (1946)

    2023  Volume 174, Issue 1-2, Page(s) 1–3

    MeSH term(s) Humans ; Neurology ; Autoimmunity
    Language English
    Publishing date 2023-11-03
    Publishing country Austria
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 123613-1
    ISSN 1563-258X ; 0254-7945 ; 0043-5341
    ISSN (online) 1563-258X
    ISSN 0254-7945 ; 0043-5341
    DOI 10.1007/s10354-023-01023-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Online: Emerging Challenges in the Diagnosis and Treatment of Autoimmune Encephalitis

    Blaabjerg, Morten / Seifert-Held, Thomas / Sellner, Johann

    2019  

    Keywords Medicine ; Neurology & clinical neurophysiology ; autoimmune encephalitis ; Limbic Encephalitis ; diagnosis ; therapy ; antibody ; testing
    Size 1 electronic resource (120 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021229857
    ISBN 9782889458301 ; 288945830X
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Multiple sclerosis at the crossroads of scientific evidence and clinical translation.

    Sellner, Johann

    Wiener medizinische Wochenschrift (1946)

    2022  Volume 172, Issue 15-16, Page(s) 327–328

    MeSH term(s) Humans ; Multiple Sclerosis/therapy
    Language English
    Publishing date 2022-10-26
    Publishing country Austria
    Document type Editorial
    ZDB-ID 123613-1
    ISSN 1563-258X ; 0254-7945 ; 0043-5341
    ISSN (online) 1563-258X
    ISSN 0254-7945 ; 0043-5341
    DOI 10.1007/s10354-022-00936-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Thesis: Diagnostic workup of patients with acute transverse myelitis

    Sellner, Johann

    spectrum of clinical presentation, neuroimaging and laboratory findings

    2009  

    Author's details Johann Sellner
    Language English
    Size 32 Bl., Ill., graph. Darst., 30 cm
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis München, Techn. Univ., Diss., 2009
    HBZ-ID HT016460399
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2010 E 2413 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.

    Hauer, Larissa / Sellner, Johann

    Drug design, development and therapy

    2022  Volume 16, Page(s) 3915–3927

    Abstract: Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disorder of the central nervous system. Disease-modifying drugs (DMDs) and subsequent adherence are crucial for preventing reversible episodes of neurological ... ...

    Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disorder of the central nervous system. Disease-modifying drugs (DMDs) and subsequent adherence are crucial for preventing reversible episodes of neurological dysfunction and delayed onset of progressive accumulation of irreversible deficits. Yet, side effects may limit their usage in clinical practice. Gastrointestinal (GI) side effects are a significant limitation of the use of dimethyl fumarate (DMF), the most frequently prescribed oral DMD in MS worldwide. Diroximel fumarate (DRF) is a second-generation oral fumaric acid ester (FAE) that was developed as a formulation with better GI tolerability. The improved tolerability is assumed to be related to a lower synthesis of gut-irritating methanol. Other explanations for DRF's lower extent of GI irritation include a more modest off-target activity due to its chemical structure. The superior GI tolerability of DRF compared to DMF could be proven in clinical trials and lead to approval of DRF for the treatment of relapsing forms of MS/relapsing-remitting MS (United States Food and Drug Administration and European Medicines Agency, respectively). Here, we summarize the mode of action of oral FAE and compare the chemical and physiological characteristics of DMF and DRF. Moreover, we discuss the adverse effects of FAE and introduce the emerging preclinical and trial data leading to the approval of DRF in MS. This article additionally reviews our current understanding of coronavirus disease 2019 (COVID-19) and the efficacy of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in people treated with FAE.
    MeSH term(s) Humans ; COVID-19 ; Dimethyl Fumarate/adverse effects ; Drug-Related Side Effects and Adverse Reactions/drug therapy ; Immunosuppressive Agents/adverse effects ; Multiple Sclerosis/drug therapy ; SARS-CoV-2 ; United States
    Chemical Substances Dimethyl Fumarate (FO2303MNI2) ; Immunosuppressive Agents
    Language English
    Publishing date 2022-11-10
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S236926
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience.

    Perncezky, Julian / Sellner, Johann

    Journal of central nervous system disease

    2022  Volume 14, Page(s) 11795735221135485

    Abstract: The high efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis (MS) is without controversy. Indeed, effective disease control was not only demonstrated in the pivotal trials but has been corroborated impressively in real- ... ...

    Abstract The high efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis (MS) is without controversy. Indeed, effective disease control was not only demonstrated in the pivotal trials but has been corroborated impressively in real-world observations. This monoclonal IgG4 antibody blocks the α4β1 integrin-mediated leukocyte-endothelial interaction and thereby inhibits the migration of immune cells to the brain parenchyma. However, treatment with natalizumab carries the risk of progressive multifocal leukoencephalopathy (PML). This potentially lethal side effect is a significant limitation for treatment initiation and long-term therapy. Natalizumab is given intravenously or subcutaneously in the standard dose of 300 mg every 4 weeks, allowing drug concentrations at levels that ensure continuous α4β1 integrin receptor saturation on the surface of immune cells. Extended-interval dosing (EID) is an emerging treatment approach that aims to mitigate the natalizumab-related PML risk by prolonging the standard infusion intervals to 6 weeks or even more. This treatment approach may abrogate the PML risk due to improved immune surveillance within the central nervous system while maintaining clinical efficacy. Moreover, even an individual interval dosing can be envisioned based on the availability of a biomarker that is capable of monitoring both safety and efficacy aspects. This review summarizes the early and encouraging evidence for EID from observational and randomized-controlled trials and discusses current limitations and upcoming challenges for introducing a tailored treatment approach.
    Language English
    Publishing date 2022-10-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2586873-1
    ISSN 1179-5735
    ISSN 1179-5735
    DOI 10.1177/11795735221135485
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.

    Sellner, Johann / Rommer, Paulus S

    Vaccines

    2021  Volume 9, Issue 2

    Abstract: Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the ... ...

    Abstract Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.
    Language English
    Publishing date 2021-01-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9020099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy.

    Schulte, Eva C / Sellner, Johann

    EBioMedicine

    2021  Volume 73, Page(s) 103635

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Viral/blood ; Antigens, CD20/metabolism ; COVID-19/drug therapy ; COVID-19/epidemiology ; COVID-19/mortality ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Disease Progression ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Multiple Sclerosis/therapy ; Rituximab/therapeutic use ; SARS-CoV-2/immunology ; Vaccination
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antibodies, Viral ; Antigens, CD20 ; COVID-19 Vaccines ; Immunologic Factors ; Rituximab (4F4X42SYQ6) ; ocrelizumab (A10SJL62JY)
    Language English
    Publishing date 2021-10-14
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2021.103635
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: "Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy."

    Bsteh, Gabriel / Sellner, Johann

    EBioMedicine

    2021  Volume 74, Page(s) 103692

    MeSH term(s) Antibodies, Monoclonal, Humanized/pharmacology ; Antigens, CD20/analysis ; B-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; Humans ; Immunity, Humoral/immunology ; Multiple Sclerosis ; Rituximab/pharmacology ; SARS-CoV-2/immunology ; Vaccination ; mRNA Vaccines/administration & dosage ; mRNA Vaccines/immunology
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antigens, CD20 ; COVID-19 Vaccines ; mRNA Vaccines ; Rituximab (4F4X42SYQ6) ; ocrelizumab (A10SJL62JY)
    Language English
    Publishing date 2021-11-10
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2021.103692
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: SARS-CoV-2 vaccination in multiple sclerosis

    Eva C. Schulte / Johann Sellner

    EBioMedicine, Vol 73, Iss , Pp 103635- (2021)

    A clearer picture for the time point during CD20 depleting therapy

    2021  

    Keywords Medicine ; R ; Medicine (General) ; R5-920
    Language English
    Publishing date 2021-11-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top